Sometimes no news is good news. That seems to be the case for Amgen Inc., which Thursday disclosed top-line Phase III data showing that Aranesp (darbepoetin alfa) did not raise safety concerns in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results